StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
KRYSBullishEarningsnews
High materiality7/10

Krystal Biotech reports strong 3Q revenue, completes pricing talks, and launches $400M buyback

Nov 2, 2026, 7:25 AM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strong quarterly revenue, cash build, and a sizable buyback, plus favorable pricing developments and positive KB113 data, collectively raise the odds of near-term incremental upside.

AI summary

What happened, with direct paths to the underlying reporting

Krystal Biotech posted a solid 3Q with $127.3 million in VYJUVEK revenue and $1.1 billion since launch, plus completed pricing negotiations in Germany and Italy. KB113 clinical data show regression in more than 80% of Gorlin syndrome basal cell carcinoma lesions, supporting therapeutic potential. The company closed the quarter with $1.2 billion in cash and investments and authorized a $400 million share repurchase, signaling robust capital flexibility and upside potential.

  • 3Q VYJUVEK revenue: $127.3M; $1.1B since launch.
  • Germany and Italy pricing negotiations completed.
  • KB113 data: regression in >80% Gorlin BCC lesions.
  • Balance sheet: $1.2B cash/investments; board approves $400M buyback.
  • Share repurchase authorization signals stronger capital return.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event